Oxford Immunotec settles with Qiagen, signs $27.5m licence

18-12-2017

Oxford Immunotec settles with Qiagen, signs $27.5m licence

designer491 / iStockphoto.com

UK-based diagnostics company Oxford Immunotec has settled a patent infringement dispute with Qiagen, a provider of sample and assay technologies for molecular diagnostics.


Oxford Immunotec, patent, patent infringement, settlement, Qiagen, licence, tuberculosis

More on this story

Jury rules Qiagen infringed two gene patents
31-08-2021

LSIPR